Plitidepsin as a successful rescue treatment for prolonged viral SARS-CoV-2 replication in a patient with previous anti-CD20 monoclonal antibody-mediated B cell depletion and chronic lymphocytic leukemia.

Pablo Guisado VascoM M Carralón-GonzálezJ Aguareles-GorinesE M Martí-BallesterosM D Sánchez-ManzanoD Carnevali-RuizM García-CocaR Barrena-PuertasR García de ViedmaJ M Luque-PinillaG Sotres-FernandezJ M Fernández-SousaX E Luepke-EstefanJ A López-MartínJ M Jimeno

Published in: Journal of hematology & oncology (2022)

Treatment with plitidepsin was well-tolerated without any further hematological or cardiovascular toxicities. This case further supports plitidepsin as a potential antiviral drug in SARS-CoV-2 patients affected by immune deficiencies and hematological malignancies.

Keyphrases

sars cov
monoclonal antibody
chronic lymphocytic leukemia
end stage renal disease
respiratory syndrome coronavirus
ejection fraction
chronic kidney disease
newly diagnosed
emergency department
case report
combination therapy
risk assessment
smoking cessation
replacement therapy
human health
adverse drug